IMCR - Immunocore eye cancer drug Kimmtrak gets approval in Australia Canada UK

The U.K. Medicines and Healthcare products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada granted marketing authorization to Immunocore's (NASDAQ:IMCR) Kimmtrak  to treat HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma, a type of cancer affecting the eye. The drug is already approved in the U.S. and EU. Kimmtrak (tebentafusp) was reviews under the FDA's Project Orbis program, which enabled concurrent review by the health authorities in partner countries which requested participation—including Australia, Canada, and the U.K., the company said in a June 8 press release. The approvals were backed by data from a phase 3 trial called IMCgp100-202.

For further details see:

Immunocore eye cancer drug Kimmtrak gets approval in Australia, Canada, UK